Circulation:TAVR术前后运动量的变化与临床预后的相关性研究

2017-06-08 MedSci MedSci原创

经皮主动脉瓣置换术(TAVR)是治疗主动脉瓣疾病最有效的方案之一。近日,在国际心血管权威杂志《Circulation》上发表了一篇关于探索TAVR术后不同的运动量对预后影响的临床研究。

经皮主动脉瓣置换术(TAVR)是治疗主动脉瓣疾病最有效的方案之一。近日,在国际心血管权威杂志《Circulation》上发表了一篇关于探索TAVR术后不同的运动量对预后影响的临床研究。

本次研究共纳入305TAVR术后的患者(平均年龄79±9岁;男性占44%STS评分:6.7%±4.2%),并在术后6个月对其基线和随访的运动能力进行了评估。运动能力是通过6分钟步行实验(6MWT)来进行评估的。通过高于(n=152,提高组)或低于(n=153,非提高组)基线到术后6个月6分钟行走的距离的中位百分比的变化,研究者将术后的患者分成两组,并对其分别进行临床预后的对比。观察的主要预后结果是术后6个月内出现的临床事件发生率,另外,根据基线的6分钟行走实验的行走距离(高于平均行走距离或者低于平均行走距离)进一步评估分析。

研究结果显示,患者术前和术后(6个月)的平均行走距离分别是204±119263±116米(Δ6MWT= 60 ±106米),其中有219名患者(72%)的行走距离有所提高。与运动量的提高减少有关的因素有基本临床特征(年龄较大、女性、慢性阻塞性肺病;p<0.05)、围手术期的大出血(p=0.009)和术后6个月新发的贫血(p=0.009)。未能提高6MWT距离的20%的患者在全因死亡(p=0.002)、心源性死亡或因心血管疾病再住院率(p=0.001)要更高。6MWT距离有所提高的低基线患者的预后要显著好于没有提高的患者(全因死亡p=0.01心血管终点事件p=0.001)。

TAVR术后有近三分之一患者的运动量耐量没有提高。这些结果表明,系统地实施TAVR术前、后的运动能力评估可能有助于改善患者的风险分层。


原始出处:

Omar.A et al.Predictors and Association with Clinical Outcomes of the Changes in Exercise Capacity Following Transcatheter Aortic Valve Replacement.Circulation.2017 June 6.Doi:https://doi.org/10.1161/CIRCULATIONAHA.116.026349

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059222, encodeId=ca3120592220d, content=<a href='/topic/show?id=739f94235ce' target=_blank style='color:#2F92EE;'>#运动量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94235, encryptionId=739f94235ce, topicName=运动量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 01 09:41:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086311, encodeId=0eb1208631113, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Feb 14 19:41:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837256, encodeId=3a47183e256d5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu May 17 14:41:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534712, encodeId=07301534e12aa, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 10 12:41:00 CST 2017, time=2017-06-10, status=1, ipAttribution=)]
    2017-11-01 xuyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059222, encodeId=ca3120592220d, content=<a href='/topic/show?id=739f94235ce' target=_blank style='color:#2F92EE;'>#运动量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94235, encryptionId=739f94235ce, topicName=运动量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 01 09:41:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086311, encodeId=0eb1208631113, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Feb 14 19:41:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837256, encodeId=3a47183e256d5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu May 17 14:41:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534712, encodeId=07301534e12aa, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 10 12:41:00 CST 2017, time=2017-06-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059222, encodeId=ca3120592220d, content=<a href='/topic/show?id=739f94235ce' target=_blank style='color:#2F92EE;'>#运动量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94235, encryptionId=739f94235ce, topicName=运动量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 01 09:41:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086311, encodeId=0eb1208631113, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Feb 14 19:41:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837256, encodeId=3a47183e256d5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu May 17 14:41:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534712, encodeId=07301534e12aa, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 10 12:41:00 CST 2017, time=2017-06-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059222, encodeId=ca3120592220d, content=<a href='/topic/show?id=739f94235ce' target=_blank style='color:#2F92EE;'>#运动量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94235, encryptionId=739f94235ce, topicName=运动量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 01 09:41:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086311, encodeId=0eb1208631113, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Feb 14 19:41:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837256, encodeId=3a47183e256d5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu May 17 14:41:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534712, encodeId=07301534e12aa, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 10 12:41:00 CST 2017, time=2017-06-10, status=1, ipAttribution=)]

相关资讯

J Hypertens:二手烟暴露与非吸烟者心血管危险因素有何关系?

尽管SHSE与心血管疾病的发病率和死亡率风险增加相关,在这个横断面研究中研究人员没有发现SHSE与血压、血脂或空腹血糖水平之间存在相关性。利用尿液中可替宁客观测量并没有改变这种相关性。需要进一步的长期的前瞻性研究来探讨SHSE作为心血管疾病危险因素的影响。

Circulation:紫杉醇洗脱球囊支架、普通球囊支架和粥样斑块切除术在股动脉疾病治疗中的比较性研究

股动脉粥样硬化在外周动脉疾病患者中较普遍。目前,紫杉醇洗脱球囊成形术、支架置入和定向斑块旋切术(DA)为股动脉疾病患者的治疗提供了新的思路,但对这些治疗手段效果的比较尚未明确。

JACC:NOACs剂量不当可能增加房颤患者的结局风险!

对于肾功能不全的房颤患者,非维生素K拮抗剂口服抗凝药(NOACs)的治疗剂量一直存在争议,服用过多会增加出血风险,而用量不够则会增加中风的风险。近日,在国际心血管权威杂志JACC上发表了一篇旨在探索NOACs在伴有肾功能受损的房颤患者中的剂量模式与相关结局,比如中风(缺血性卒中和全身性栓塞)和大出血之间关系的大样本临床研究。

HEART:中国学者证实ERP与动脉粥样硬化危险因素的长期预后相关性

既往研究表明早期复极化模式(ERP)在无结构性心脏病患者中与突发心源性死亡(SCD)相关。然而,尚未有研究证实ERP在动脉粥样硬化性心脏病高危人群中的预后价值。

CIRC RES:首次在表观遗传水平系统证实血液免疫细胞与急性冠脉综合征的相关性!

急性冠脉综合征(ACS)是全球死亡的主要原因。免疫功能在ACS的发生发展过程中起到重要作用,但在该过程中表观遗传是否对血液免疫细胞有调控作用尚属未知。

JAHA:患有糖尿病的血液透析患者血糖控制与心血管结局之间的关系!

由此可见,HbA1c水平升高与糖尿病患者较高的心血管死亡率和心肌梗死发生率相关,但与卒中、外周动脉疾病或全因死亡率无显著相关性。